Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: US FDA Approvals Of Mavyret, Idhifa, Vyxeos Headline Week Of Breakthroughs, Hematology And Hematology BTDs

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV
Fast-To-Market Play For AstraZeneca's Acalabrutinib With MCL Filing
Celgene, Agios Ready For Enasidenib Launch After Early Approval
AstraZeneca Hopes Imfinzi Breakthrough Get Can Burn Off MYSTIC Failure
AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients
ALEX Ups The Ante For Alecensa In ALK+ NSCLC
Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response
Portola Defends AndexXa Antidote Safety, Says Thrombotic Events In Line
Celator Shines At ASCO, Highlights Upside For Jazz


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts